What is immune-mediated inflammatory myopathy?

What is Immune-Mediated Inflammatory Myopathy?

Immune-mediated inflammatory myopathies (IIM), also known as idiopathic inflammatory myopathies, are a heterogeneous group of rare, systemic autoimmune diseases characterized by immune-mediated damage to skeletal muscle, resulting in proximal muscle weakness, elevated muscle enzymes (particularly creatine kinase), and frequently involving extramuscular organs including skin, lungs, heart, and joints. 1, 2

Major Subtypes

The classification of IIM has evolved significantly, with five major recognized subtypes 3:

1. Dermatomyositis (DM)

• Characterized by distinctive skin manifestations including:
  • Gottron papules (raised violaceous papules over knuckles)
  • Heliotrope rash (periorbital edema with violaceous discoloration)
  • Photosensitive erythematous rash with poikiloderma
  • Periungual telangiectasias
• Symmetric proximal muscle weakness developing over weeks to months
• Can occur with or without muscle involvement (amyopathic DM)
• Associated with increased malignancy risk, particularly in anti-TIF1γ antibody-positive patients 2

2. Polymyositis (PM)

• Symmetric proximal muscle weakness without skin manifestations
• Distinct immunohistopathologic pattern: CD8+ cytotoxic T cells invading non-necrotic muscle fibers
• Important caveat: PM is now recognized as overdiagnosed historically; many cases previously labeled as PM are actually immune-mediated necrotizing myopathy or inclusion body myositis 2

3. Immune-Mediated Necrotizing Myopathy (IMNM)

• Severe myopathy with prominent muscle necrosis but minimal inflammatory infiltrate on biopsy
• Markedly elevated creatine kinase levels (often >10 times upper limit of normal)
• Acute to subacute onset of severe proximal weakness
• Triggered by:
  • Statin medications (anti-HMGCR antibodies)
  • Viral infections
  • Malignancy
  • Connective tissue diseases
• Requires aggressive immunosuppression despite minimal inflammation on biopsy 2

4. Sporadic Inclusion Body Myositis (sIBM)

• Distinctive pattern: asymmetric weakness affecting both proximal AND distal muscles
• Insidious onset after age 50 years
• Male predominance (3:1 ratio)
• Classic pattern: atrophy of forearm flexors, finger flexors, and quadriceps
• Dysphagia is common and can lead to significant morbidity (aspiration pneumonia, feeding tube dependence)
• Pathology shows degenerative features: rimmed vacuoles, amyloid-β and phosphorylated tau accumulation
• Critical distinction: Generally resistant to immunosuppressive therapy unlike other IIM subtypes 2

5. Antisynthetase Syndrome

• Defined by presence of anti-aminoacyl-tRNA synthetase antibodies (most commonly anti-Jo-1)
• Clinical triad: myositis, interstitial lung disease, and inflammatory arthritis
• Additional features: mechanic's hands, Raynaud phenomenon, fever
• Unique histopathologic feature: perifascicular necrosis 4

Juvenile Dermatomyositis (JDM)

Affects children under 18 years with distinct features:

• More severe vasculopathy than adult DM
• Calcinosis cutis (calcium deposits in skin/subcutaneous tissue)
• Cutaneous vasculitis and ulcerations
• Gastrointestinal vasculopathy risk 2

Diagnostic Framework

The 2017 EULAR/ACR Classification Criteria 1 provide a validated approach:

• Uses weighted scoring system for clinical, laboratory, and histopathologic features
• Probability cutoff of 55% (score ≥5.5 without biopsy, ≥6.7 with biopsy) indicates "probable IIM"
• Sensitivity/specificity: 87%/82% without biopsies, 93%/88% with biopsies
• Allows classification into definite, probable, or possible IIM

Role of Myositis-Specific Autoantibodies

Autoantibodies are critical for diagnosis, subtype classification, and prognosis 2:

• Define distinct clinical phenotypes
• Predict extramuscular organ involvement (particularly pulmonary and cardiac)
• Guide long-term prognosis
• Examples:
  • Anti-TIF1γ: Associated with malignancy risk
  • Anti-HMGCR: Statin-associated necrotizing myopathy
  • Anti-SRP: Severe necrotizing myopathy
  • Anti-Mi2: Generally favorable prognosis in DM

Extramuscular Manifestations

IIM are systemic diseases with potential involvement of:

• Pulmonary: Interstitial lung disease (can be life-threatening), aspiration pneumonia
• Cardiac: Myocarditis, arrhythmias, diastolic dysfunction
• Gastrointestinal: Dysphagia (cricopharyngeal dysfunction), vasculopathy in JDM
• Constitutional: Fever, weight loss, fatigue 2

Key Clinical Pitfalls

1. Misdiagnosing muscular dystrophies with inflammation as IIM - requires careful exclusion of genetic myopathies
2. Overdiagnosing polymyositis - many historical PM cases are actually IMNM or IBM
3. Missing IBM in patients labeled as treatment-resistant PM - look for distal weakness pattern
4. Failing to screen for malignancy in high-risk patients (particularly DM with anti-TIF1γ)
5. Discontinuing statins in IMNM without recognizing need for immunosuppression - stopping the trigger alone is insufficient 2

Prognosis Determinants

• IBM and IMNM: Prognosis primarily determined by functional impairment and muscle weakness
• DM, antisynthetase syndrome, and overlap myositis: Life-threatening potential due to systemic involvement (particularly interstitial lung disease, cardiac involvement, malignancy) 3